No Data
Cyfuse Biomedical KK: Collection of questions and answers on full-year financial results for the fiscal year ending 2024/12
Cyfuse Biomedical KK: Extraordinary Report
Stocks that moved or were traded in the first half of the session.
*Mitsubishi Corporation <8058> 2594.5 +214 Expectations of increased purchases by Mr. Buffett lead major trading companies to buy first. *Marubeni Corporation <8002> 2468 +178.5 Mr. Buffett's letter to investors is regarded as material. *Itochu Corporation <8001> 6550 +409 Major general trading companies show Mr. Buffett's willingness to increase purchases. *Sumitomo Corporation <8053> 3440 +196 Following hints of Mr. Buffett raising his shareholding limit. *Nexela Pharma <4565> 887 +
SaiFuse has fallen for the first time in four days, with increased margin requirements in Margin Trading, causing concerns over increased trading burdens.
Saifuse <4892.T> has fallen for the first time in four days, temporarily dropping 104 yen to 956 yen. The Tokyo Stock Exchange announced after the market close on the 21st of last week that it would impose regulatory measures on Margin Trading starting from the 25th. The increase in trading burden due to heightened margin requirements has caused concern. The Tokyo Stock Exchange stated that from the trades on the 25th, the margin rate for new Sell and Buy orders conducted through Margin Trading would be raised to over 50% (with at least 20% in cash). As of 9:16 AM, the stock price was down from the previous.
Cyfuse Biomedical KK: Financial results briefing materials for the fiscal year ending 2024/12
Cyfuse Biomedical KK: Financial results presentation materials for the fiscal year ending 2024/12 (summary version)